Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ(2) tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most frequently involved site (63.9% versus 63.4%) in ...
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone m...
© 2017, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Introduct...
Bisphosphonates are used to reduce skeletal-related events in patients with bone-consuming diseases,...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Background: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of oste...
The osteonecrosis of the jaws (ONJ) is an adverse side effect of long-term bisphosphonate therapy (B...
Objective(s)Bisphosphonates are frequently used worldwide mostly in osteoporosis and skeletal bone m...
BACKGROUND: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of ...
BACKGROUND: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of ost...
Bisphosphonates (BPs) are used to treat metabolic bone diseases, such as osteoporosis. In this study...
Background: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) presents the clinician with sig...
BACKGROUND: Biphosphonate-related osteonecrosis of the jaw (BRONJ) is a potential side effect associ...
Objective: Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ) is typically a chronic soft tiss...
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone m...
© 2017, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Introduct...
Bisphosphonates are used to reduce skeletal-related events in patients with bone-consuming diseases,...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Invasive local procedures are often reported in clinical history of patients suffering from Bisphosp...
Background: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of oste...
The osteonecrosis of the jaws (ONJ) is an adverse side effect of long-term bisphosphonate therapy (B...
Objective(s)Bisphosphonates are frequently used worldwide mostly in osteoporosis and skeletal bone m...
BACKGROUND: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of ...
BACKGROUND: Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of ost...
Bisphosphonates (BPs) are used to treat metabolic bone diseases, such as osteoporosis. In this study...
Background: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) presents the clinician with sig...
BACKGROUND: Biphosphonate-related osteonecrosis of the jaw (BRONJ) is a potential side effect associ...
Objective: Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ) is typically a chronic soft tiss...
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone m...
© 2017, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Introduct...
Bisphosphonates are used to reduce skeletal-related events in patients with bone-consuming diseases,...